A 50-year-old male with chronic schizophrenia has been stable on paliperidone palmitate long-acting injectable 156 mg monthly for the past three years. He has had no hospitalizations, no emergency department visits, and his PANSS total score has been consistently between 58 and 64, indicating mild-to-moderate residual positive and negative symptoms. At this visit, he reports he spends most days alone in his apartment, has no social contacts outside of his monthly injection appointment and a weekly visit from his case manager, has not worked in over 10 years, and describes his typical day as watching television and smoking. He reports he is satisfied with his current medication because he has not been hospitalized and denies subjective distress. His case manager reports he has declined repeated referrals to psychosocial rehabilitation programs. The PMHNP is evaluating overall treatment outcomes for this patient. Which evaluation framework is most clinically appropriate?